Latest Conference Articles

New formulation associated with delayed time to impending relapse, as well as improvements on measures of symptom severity and treatment response.

New validated assessment tools allow clinicians to better assess the level of real-life functioning in patients with schizophrenia.

Mental health advocate calls for a multidisciplinary approach to treating patients with severe mental illness.

Clinicians who treat patients with atypical antipsychotics should be aware of the weight gain potential associated with each medication in this class, and select the most appropriate medication to ensure patient compliance and prevent relapse.

Study reveals that psychiatric comorbidities are common in patients with terminal cancer and illustrates the important role psychiatrists can play in palliative and end-of-life care.

Study indicates that nonspecific physical symptoms such as pain, weakness, and shortness of breath may indicate PTSD or depression.

Posters present results of clinical trials that examined lurasidone as monotherapy and as part of combination therapy in patients with bipolar 1 depression with or without rapid cycling and without psychotic features.

Mental health expert says that the key to improving care is to integrate medical care into mental health settings, and introduce mental health care competence into primary care.

A poster presented at the American Psychiatric Association 64th Institute on Psychiatric Services examined whether depot medications work better than oral agents in schizophrenia.

The oral disease-modifying drug under development for the treatment of relapsing-remitting multiple sclerosis, teriflunomide, was not superior to interferon beta-1a in risk of treatment failure.

In the course of a 24-week cessation of treatment with the humanized monoclonal antibody, natalizumab, in patients with RRMS, pharmacokinetic, pharmacodynamic, and serum immune parameters normalized by 4 months.

People discharged from the hospital with MS are 30% less likely to have had a myocardial infarction and 58% less likely to have ischemic heart disease.

Treatment with the investigational oral treatment for relapsing-remitting multiple sclerosis, dimethyl fumarate (aka BG-12), yielded significant reductions in the annualized relapse rate and risk of relapse.

After a 24-week cessation of natalizumab treatment, a high rate of MRI and clinical disease activity recurs in patients with multiple sclerosis.

The monoclonal antibody, alemtuzumab, significantly reducesthe number of relapses and the accumulation of disability in patients with relapsing-remitting multiple sclerosis who had relapsed on prior therapy.

The once-daily oral MS drug, fingolimod, slows brain volume loss in patients with MS, regardless of inflammatory activity.

The once-daily oral MS drug, fingolimod, reduces annualized relapse rates in patients who achieved unsatisfactory responses when treated with other disease-modifying therapies or who had been treated for an extended period of time.

Treatment with the investigational oral drug for RRMS, dimethylfumarate (aka BG-12), yielded significant reductions in inflammatory disease activity using MRI outcomes.

Cholestyramine and activated charcoal can be used to virtually eliminate the long half-life oral investigational multiple sclerosis drug, teriflunomide, from the plasma in 11 days.

People with MS frequently reported having both episodic and chronic migraines, with Hispanic MS patients experiencing significantly more chronic migraines.

In clinical trials, treatment of patients with the oral disease-modifying therapy, teriflunomide, for relapsing forms of multiple sclerosis can result in hair loss/thinning, but this side effect is generally manageable.

Dr. John R. Rinker, II Assistant Professor of Neurology Outlines some highlights of his study The Nature of MS: Epidemiology, Diagnosis, Natural History and Clinical Course.

In the first long-term active-comparator trial of efficacy and augmentation in restless leg syndrome (RLS), outcomes with pregabalin were better than those observed with pramipexole.

Although the intra-cerebral hemorrhage (ICH) score at hospital admission is typically used to estimate the potential prognosis in stroke patients, a new study suggests that the 24-hour ICH score is a more accurate assessment.

According to a randomized, controlled clinical trial reported at the Emerging Science session, pregabalin was found effective in relieving chronic neuropathic pain and pain-related sleep disturbances associated with spinal cord injury.

Results from the FREEDOMS II trial found oral fingolimod administered at a daily dose of 0.5 mg to reduce relapse rates by almost 50% in patients with relapsing-remitting multiple sclerosis (RRMS).

Mark F. Mehler, MD, discussed how brain and behavior are becoming better understood through the emerging discipline of epigenetics.

The 2012 Annual Meeting of the American Academy of Neurology presented a phase 3 randomized, double-blind clinical trial which found that levodopa-carbidopa intestinal gel was more effective than standard oral levodopa-carbidopa.

An investigational oral drug for multiple sclerosis (MS), called ONO-4641, reduced the number of lesions detected on magnetic resonance imaging (MRI) scans

Updated guidelines for prevention of chronic migraine headache were unveiled during the 2012 Annual Meeting of the American Academy of Neurology.